Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained

European Journal of Cancer

Volumn 33, Issue 10, 1997, Pages 1693-1698

  Taylor, C W ^a   Wang, L M ^b   List, A F ^a   Fernandes, D ^b   Paine Murrieta, G D ^a   Johnson, C S ^a   Capizzi, R L ^c  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c US Bioscience   (United States)

Author keywords

Amifostine; Ovarian cancer; Paclitaxel; Scid mouse

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; AMIFOSTINE; DNA; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BURST FORMING UNIT E; CANCER CELL; COLONY FORMING UNIT GEMM; CONTROLLED STUDY; CYTOTOXICITY; DNA STRAND BREAKAGE; DRUG MEGADOSE; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; LUNG FIBROBLAST; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; SCID MOUSE;

AMIFOSTINE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; CELL CULTURE TECHNIQUES; CELL DEATH; CYTOPROTECTION; FEMALE; FIBROBLASTS; HEMATOPOIETIC STEM CELLS; HUMANS; LUNG NEOPLASMS; MICE; MICE, SCID; OVARIAN NEOPLASMS; PACLITAXEL; RADIATION-SENSITIZING AGENTS; TUMOR CELLS, CULTURED;

EID: 0031427376     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00221-9     Document Type: Article

References (26)

1. Arbuck SG, Canetta R, Onetto N, Christian MC. Current dosage and schedule issues in the development of paclitaxel (Taxol). Semin Oncol 1993, 20, 31-39.
2. Buzdar AU, Holmes FA, Hortobagyi GN. Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience. Semin Oncol 1995, 22, 101-104.
3. Capizzi RL. Amifostine: the preclinical basis for broad spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Semin Oncol 1994, 21 (5 Suppl. 11), 8-15.
4. Capizzi RL. Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (ethyol): clinical experiences. Semin Oncol 1994, 21, 8-15.
5. Capizzi RL, Scheffler BJ, Schein PS. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy. Cancer 1993, 72 (Suppl.), 3495-3501.
6. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987, 47, 936-942.
7. DeNeve WJ, Everett CK, Suminski JE, Valeriote FA. Influence of WR2721 on DNA cross-linking by nitrogen mustard in normal mouse bone marrow and leukemia cells in vivo. Cancer Res 1988, 48, 6002-6005.
8. DiPaolo R, Rodriguez R, Recia A, et al. A Phase I study of amifostine and paclitaxel in patients with advanced malignancies. Proc Am Soc Clin Oncol 1996, in press.
9. Holwitt EA, Koda E, Swenberg CE. Enhancement of topoisomerase I-mediated unwinding of supercoiled DNA by the radioprotector WR-33278. Radiat Res 1990, 124, 107-109.
10. Johnson DH, Chang AY, Ettinger DS. Taxol (paclitaxel) in the treatment of lung cancer: The Eastern Cooperative Oncology Group experience. Ann Oncol 1994, 5, S45-S50.
11. Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatininduced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996, 14, 2101-2112.
12. Kohn KW. Principles and practice of DNA filter elution. Pharmacol Ther 1991, 49, 55-77.
13. List AF, Heaton R, Glinsmann-Gibson B, Capizzi RL, Amifostine is a novel stimulant of bone marrow progenitor growth in myelodysplastic syndromes. Proc Am Soc Hematol 1995, 86, 335 (1327).
14. List AF, Heaton R, Glinsmann-Gibson B, Capizzi R. Amifostine stimulates formation of multipotent progenitors and generates macroscopic colonies in normal and myelodysplastic bone marrow. Proc Am Soc Clin Oncol 1996, in press.
15. Liu TF, Liu Y, He S. The use of radiation with or without WR-2721 in advanced rectal cancer. Cancer 1992, 69, 2820-2825.
16. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Eng J Med 1996, 334, 1-6.
17. Pike BL, Robinson WA . Human bone marrow colony growth in agar-gel. J Cell Physiol 1970, 76, 77-84.
18. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995, 332, 1004-1014.
19. Shaw LM, Glover DJ, Turrisi A, et al. Pharmacokinetics of WR-2721. Pharmacol Ther 1988, 39, 195-201.
20. Shigematsu N, Schwartz JL, Grdina DJ. Protection against radiation-induced mutagenesis at the hprt locus by spermine and N,N″-(dithiodi-2,1-ethanediyl)bis-1,3-propanediamine (WR-33278). Mutagenesis 1994, 9, 355-360.
21. Shpall EJ, Stemmer SM, Hami L, et al. Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Blood 1994, 83, 3132-3137.
22. Sledge GW, Jr, Robert N, Sparano JA, et al. Eastern cooperative oncology group studies of paclitaxel and doxorubicin in advanced breast cancer. Semin Oncol 1995, 22, 105-108.
23. Taetle R, Rosen F, Abramson I, Venditti J, Howell S. Use of nude mouse xenografts as preclinical drug screens: in vivo activity of established chemotherapeutic agents against melanoma and ovarian carcinoma xenografts. Cancer Treat Rep 1987, 71, 297-304.
24. Tinwell H, Ashby J. Genetic toxicity and potential carcinogenicity of Taxol. Carcinogenesis 1994, 15, 1499-1501.
25. Treskes M, Boven E, van de Loosdrecht AA, et al. Effects of the modulating agent WR2721 on myelotoxicity and antitumor activity in carboplatin-treated mice. Eur J Cancer 1994, 30A, 183-187.
26. Treskes M, Nijtmans LGJ, Fichtinger-Schepman AMJ, van der Vijgh WJF. Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulfate and diethyldithiocarbamate. Biochem Pharmacol 1992, 43, 1013-1019.